We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
N -(((1 S ,5 R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)-3-dodecan/tetradecanamido- N , N -dimethylpropan-1-aminium Bromide.
- Authors
Nikitina, Liliya E.; Gilfanov, Ilmir R.; Pavelyev, Roman S.; Lisovskaya, Svetlana A.; Trizna, Elena Y.; Rakhmatullin, Ilfat Z.; Klochkov, Vladimir V.; Davletshin, Rustam R.; Babaeva, Olga B.; Kolesnikova, Alena I.; Ostolopovskaya, Olga V.; Frolova, Larisa L.; Kayumov, Airat R.
- Abstract
The syntheses of the title compounds were performed using lauric and myristic acids. The compounds obtained were characterized using 1H-, 13C-NMR and 2D 1H-1H COSY, 1H-13C HSQC NMR, IR, and high-resolution mass spectrometry. Both compounds exhibited bactericidal activity on S. aureus comparable to that of a reference drug (miramistin). Compound 10, with lauric acid fragment, had a 16-fold higher activity on P. aeruginosa compared to compound 11, which in turn contains myristic acid fragment (with minimum inhibitory concentrations of 32 and 512 μg/mL, respectively). Compound 11 exhibited a pronounced activity against all types of fungi (higher than the activity of miramistin), while the activity of compound 10 was considerably lower. Thus, compound 11 can serve as a promising antimicrobial agent for the treatment of various fungal and staphylococcal infections, while compound 10 is of interest to treat P. aeruginosa-associated infections.
- Subjects
LAURIC acid; STAPHYLOCOCCAL diseases; MYCOSES; BROMIDES; MASS spectrometry
- Publication
Molbank, 2023, Vol 2023, Issue 3, pM1704
- ISSN
1422-8599
- Publication type
Article
- DOI
10.3390/M1704